Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics, Inc.
9350 Kirby Drive
Suite 300
Houston, TX 77054
United States
713 400 6400
https://markertherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 8
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Juan F. Vera M.D. | Co-Founder, CEO, President, Treasurer, Secretary & Director | 399.25k | N/D | 1980 |
| Ms. Elizabeth Donnelly | Director of Administration | N/D | N/D | N/D |
| Dr. Maria-Bernadette Madel | Director of Corporate Operations & External Communications | N/D | N/D | 1990 |
| Mr. Edmund Cheung | Vice President of Human Resources | N/D | N/D | N/D |
| Dr. Nadia Agopyan Ph.D. | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
| Dr. Monic Stuart M.D. | Chief Medical Officer | N/D | N/D | N/D |
| Patricia Allison | Head of Clinical Operations | N/D | N/D | N/D |
| Dr. Robert Z. Florkiewicz Sr. | Senior Director of Molecular Biology & Virology | N/D | N/D | N/D |
Descripción
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Gestión corporativa
La calificación ISS Governance QuickScore de Marker Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
